Characteristics of patients with ALL, overall and by DI
| Variable . | Entire cohort (n = 644) . | Normal DI (n = 455) . | High DI (n = 189) . | P value . |
|---|---|---|---|---|
| Age at diagnosis, median (range), y | 5 (1-18) | 5 (1-18) | 4 (1-18) | .7 |
| Age at study enrollment, median (range), y | 6 (2-19) | 6 (2-19) | 6 (2-19) | .9 |
| Length of follow-up from study enrollment, median (range), y | 7.9 (0.2-13.0) | 7.9 (0.4-10.6) | 7.9 (0.2-13.0) | .7 |
| Male, n (%) | 444 (68.9) | 312 (68.6) | 132 (69.8) | .8 |
| Race/ethnicity, n (%) | ||||
| African American or Black | 115 (17.9) | 78 (17.1) | 37 (19.6) | .2 |
| Asian | 98 (15.2) | 76 (16.7) | 22 (11.6) | |
| Hispanic | 215 (33.4) | 143 (31.4) | 72 (38.1) | |
| Non-Hispanic White | 216 (33.5) | 158 (34.7) | 58 (30.7) | |
| ALL subtype, n (%) | ||||
| B-lymphoblastic leukemia | 569 (89.2) | 399 (88.9) | 170 (90.0) | .5 |
| T-lymphoblastic leukemia | 69 (10.8) | 50 (11.1) | 19 (10.1) | .7 |
| NCI risk group, n (%) | ||||
| Standard risk | 377 (59.0) | 263 (58.2) | 114 (60.7) | .5 |
| Cytogenetics, n (%) | ||||
| Favorable | 262 (43.3) | 197 (45.7) | 65 (37.4) | .07 |
| Neutral | 307 (50.7) | 213 (49.4) | 94 (54.0) | |
| Unfavorable | 36 (6.0) | 21 (4.9) | 15 (8.6) | |
| Treatment interruptions during months 1-4 | ||||
| Patients, n (%) | 163 (25.3) | 110 (24.2) | 53 (28.0) | .6 |
| Days, mean (±SD) | 5.5 (9.0) | 5.3 (9.2) | 6.1 (8.5) | .3 |
| Treatment interruptions during months 5-6 | ||||
| Patients, n (%) | 156 (24.4) | 93 (20.5) | 63 (34.1) | <.001 |
| Days, mean (±SD) | 2.7 (6.2) | 2.3 (6.2) | 3.6 (6.0) | .02 |
| Variable . | Entire cohort (n = 644) . | Normal DI (n = 455) . | High DI (n = 189) . | P value . |
|---|---|---|---|---|
| Age at diagnosis, median (range), y | 5 (1-18) | 5 (1-18) | 4 (1-18) | .7 |
| Age at study enrollment, median (range), y | 6 (2-19) | 6 (2-19) | 6 (2-19) | .9 |
| Length of follow-up from study enrollment, median (range), y | 7.9 (0.2-13.0) | 7.9 (0.4-10.6) | 7.9 (0.2-13.0) | .7 |
| Male, n (%) | 444 (68.9) | 312 (68.6) | 132 (69.8) | .8 |
| Race/ethnicity, n (%) | ||||
| African American or Black | 115 (17.9) | 78 (17.1) | 37 (19.6) | .2 |
| Asian | 98 (15.2) | 76 (16.7) | 22 (11.6) | |
| Hispanic | 215 (33.4) | 143 (31.4) | 72 (38.1) | |
| Non-Hispanic White | 216 (33.5) | 158 (34.7) | 58 (30.7) | |
| ALL subtype, n (%) | ||||
| B-lymphoblastic leukemia | 569 (89.2) | 399 (88.9) | 170 (90.0) | .5 |
| T-lymphoblastic leukemia | 69 (10.8) | 50 (11.1) | 19 (10.1) | .7 |
| NCI risk group, n (%) | ||||
| Standard risk | 377 (59.0) | 263 (58.2) | 114 (60.7) | .5 |
| Cytogenetics, n (%) | ||||
| Favorable | 262 (43.3) | 197 (45.7) | 65 (37.4) | .07 |
| Neutral | 307 (50.7) | 213 (49.4) | 94 (54.0) | |
| Unfavorable | 36 (6.0) | 21 (4.9) | 15 (8.6) | |
| Treatment interruptions during months 1-4 | ||||
| Patients, n (%) | 163 (25.3) | 110 (24.2) | 53 (28.0) | .6 |
| Days, mean (±SD) | 5.5 (9.0) | 5.3 (9.2) | 6.1 (8.5) | .3 |
| Treatment interruptions during months 5-6 | ||||
| Patients, n (%) | 156 (24.4) | 93 (20.5) | 63 (34.1) | <.001 |
| Days, mean (±SD) | 2.7 (6.2) | 2.3 (6.2) | 3.6 (6.0) | .02 |
NCI risk group includes both B-cell and T-cell ALL. Favorable cytogenetics included t(12;21); hyperdiploidy; trisomy 4 and 10; or trisomy 4, 10, and 17. Unfavorable cytogenetics included t(9;22), t(4;11), hypodiploidy, or extreme hypodiploidy. Neutral cytogenetics implied absence of favorable or unfavorable cytogenetics. Data were missing across ALL subtype (n = 6; all in normal DI group), NCI risk group (n = 5, 3 in normal DI group and 2 in high DI group), and cytogenetics (n = 39, 24 in normal DI group and 15 in high DI group). Proportions exclude missing data. P value compares characteristics between patients in normal DI and high DI groups.
SD, standard deviation.